Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Growth Retardation | 19 | 2017 | 73 | 3.520 |
Why?
|
| Endothelin-1 | 8 | 2016 | 42 | 2.110 |
Why?
|
| Uterus | 11 | 2017 | 232 | 2.070 |
Why?
|
| Placenta | 15 | 2017 | 203 | 1.970 |
Why?
|
| Endothelin A Receptor Antagonists | 5 | 2016 | 9 | 1.460 |
Why?
|
| Pregnancy | 42 | 2024 | 3244 | 1.100 |
Why?
|
| Pyrrolidines | 7 | 2016 | 61 | 1.070 |
Why?
|
| Receptor, Endothelin A | 5 | 2016 | 21 | 1.020 |
Why?
|
| Nitric Oxide Synthase | 6 | 2011 | 124 | 0.980 |
Why?
|
| Reperfusion Injury | 5 | 2017 | 148 | 0.880 |
Why?
|
| Pregnancy Complications | 8 | 2024 | 365 | 0.850 |
Why?
|
| Fetal Diseases | 4 | 2019 | 71 | 0.750 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2016 | 1255 | 0.710 |
Why?
|
| Platelet Activating Factor | 3 | 2012 | 53 | 0.640 |
Why?
|
| Fetal Monitoring | 2 | 2019 | 20 | 0.630 |
Why?
|
| Heart Rate, Fetal | 2 | 2019 | 18 | 0.620 |
Why?
|
| Umbilical Cord | 1 | 2019 | 39 | 0.600 |
Why?
|
| NG-Nitroarginine Methyl Ester | 6 | 2011 | 45 | 0.580 |
Why?
|
| Maternal-Fetal Exchange | 3 | 2016 | 77 | 0.560 |
Why?
|
| Receptor, Endothelin B | 4 | 2008 | 5 | 0.560 |
Why?
|
| Rats | 16 | 2016 | 4072 | 0.560 |
Why?
|
| Infant, Premature | 3 | 2019 | 306 | 0.550 |
Why?
|
| Endothelin Receptor Antagonists | 6 | 2010 | 11 | 0.530 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 237 | 0.510 |
Why?
|
| Fetal Development | 2 | 2016 | 37 | 0.470 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 84 | 0.460 |
Why?
|
| Amniotic Fluid | 3 | 2001 | 29 | 0.450 |
Why?
|
| Pregnancy, Animal | 2 | 2008 | 58 | 0.420 |
Why?
|
| Ischemia | 1 | 2016 | 262 | 0.410 |
Why?
|
| Fetal Weight | 6 | 2017 | 16 | 0.410 |
Why?
|
| Azepines | 3 | 2012 | 29 | 0.400 |
Why?
|
| Uterine Diseases | 1 | 2013 | 19 | 0.390 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2013 | 95 | 0.370 |
Why?
|
| Fetal Organ Maturity | 3 | 2001 | 4 | 0.370 |
Why?
|
| Female | 43 | 2024 | 51570 | 0.350 |
Why?
|
| Enzyme Inhibitors | 4 | 2011 | 642 | 0.350 |
Why?
|
| Indoles | 3 | 2012 | 334 | 0.350 |
Why?
|
| Inclusion Bodies | 2 | 2001 | 31 | 0.330 |
Why?
|
| Gestational Age | 7 | 2005 | 341 | 0.320 |
Why?
|
| Phospholipids | 2 | 2001 | 109 | 0.320 |
Why?
|
| Pregnancy Outcome | 8 | 2012 | 277 | 0.320 |
Why?
|
| Fetus | 3 | 2008 | 237 | 0.300 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 3 | 2001 | 58 | 0.300 |
Why?
|
| Animals | 21 | 2017 | 28902 | 0.290 |
Why?
|
| Placental Insufficiency | 1 | 2008 | 4 | 0.280 |
Why?
|
| Fetal Hypoxia | 2 | 2008 | 14 | 0.270 |
Why?
|
| Lung | 3 | 2001 | 1407 | 0.270 |
Why?
|
| Gene Expression | 2 | 2012 | 1320 | 0.270 |
Why?
|
| RNA, Messenger | 6 | 2016 | 2063 | 0.260 |
Why?
|
| Infant, Newborn | 10 | 2024 | 2531 | 0.260 |
Why?
|
| Fetal Death | 5 | 2013 | 55 | 0.260 |
Why?
|
| Cesarean Section | 4 | 2020 | 162 | 0.230 |
Why?
|
| Organ Size | 4 | 2017 | 370 | 0.220 |
Why?
|
| Ovary | 1 | 2006 | 260 | 0.210 |
Why?
|
| Xanthomatosis, Cerebrotendinous | 1 | 2024 | 4 | 0.210 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2024 | 9 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2012 | 889 | 0.200 |
Why?
|
| Hypoxia | 2 | 2007 | 699 | 0.200 |
Why?
|
| Amniocentesis | 2 | 2001 | 31 | 0.200 |
Why?
|
| Twins | 2 | 2000 | 64 | 0.190 |
Why?
|
| Blood Pressure | 5 | 2004 | 910 | 0.190 |
Why?
|
| Up-Regulation | 1 | 2005 | 743 | 0.180 |
Why?
|
| Blood Flow Velocity | 3 | 2008 | 179 | 0.170 |
Why?
|
| Triplets | 1 | 2000 | 8 | 0.160 |
Why?
|
| Labor, Obstetric | 1 | 2000 | 49 | 0.160 |
Why?
|
| Endothelins | 1 | 2000 | 26 | 0.160 |
Why?
|
| Analysis of Variance | 3 | 2010 | 889 | 0.150 |
Why?
|
| Peroxidase | 3 | 2017 | 54 | 0.150 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2019 | 4 | 0.150 |
Why?
|
| Hypertension | 4 | 2000 | 778 | 0.150 |
Why?
|
| Pulmonary Surfactants | 2 | 1996 | 22 | 0.140 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 1997 | 111 | 0.140 |
Why?
|
| Labor, Induced | 1 | 1999 | 34 | 0.140 |
Why?
|
| Diabetes, Gestational | 1 | 2019 | 51 | 0.140 |
Why?
|
| Pain Management | 1 | 2020 | 194 | 0.140 |
Why?
|
| Government Regulation | 1 | 1998 | 49 | 0.140 |
Why?
|
| Abortion, Legal | 1 | 1998 | 30 | 0.140 |
Why?
|
| Antiphospholipid Syndrome | 2 | 1995 | 17 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1998 | 27 | 0.140 |
Why?
|
| Pheochromocytoma | 1 | 1998 | 53 | 0.130 |
Why?
|
| Binding, Competitive | 2 | 2008 | 136 | 0.130 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 89 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1998 | 84 | 0.130 |
Why?
|
| Antihypertensive Agents | 2 | 1997 | 267 | 0.130 |
Why?
|
| Mice, Inbred C3H | 2 | 2017 | 370 | 0.120 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 1996 | 14 | 0.120 |
Why?
|
| Antibodies, Anticardiolipin | 2 | 1995 | 4 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 520 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2008 | 780 | 0.120 |
Why?
|
| Glycogen | 1 | 2016 | 58 | 0.120 |
Why?
|
| Mice, Mutant Strains | 2 | 2013 | 217 | 0.120 |
Why?
|
| Nucleic Acids | 1 | 2016 | 36 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 539 | 0.110 |
Why?
|
| Rh Isoimmunization | 1 | 1995 | 5 | 0.110 |
Why?
|
| Nitric Oxide | 2 | 2011 | 286 | 0.110 |
Why?
|
| alpha-Fetoproteins | 1 | 1995 | 48 | 0.110 |
Why?
|
| Adult | 14 | 2024 | 29564 | 0.110 |
Why?
|
| Humans | 24 | 2024 | 98135 | 0.100 |
Why?
|
| Microspheres | 2 | 2005 | 91 | 0.100 |
Why?
|
| Ethics, Medical | 1 | 1996 | 292 | 0.100 |
Why?
|
| Antithrombin III Deficiency | 1 | 1993 | 3 | 0.100 |
Why?
|
| Receptors, Endothelin | 3 | 2010 | 12 | 0.100 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1993 | 13 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2008 | 1815 | 0.100 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 48 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2016 | 489 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2013 | 98 | 0.090 |
Why?
|
| Thromboembolism | 1 | 1993 | 124 | 0.090 |
Why?
|
| Heparin | 1 | 1993 | 182 | 0.090 |
Why?
|
| Complement C5 | 1 | 2012 | 14 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1109 | 0.090 |
Why?
|
| Calcinosis | 1 | 2013 | 220 | 0.090 |
Why?
|
| Ligands | 1 | 2013 | 486 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2002 | 1784 | 0.090 |
Why?
|
| Hyperaldosteronism | 1 | 1991 | 14 | 0.090 |
Why?
|
| Mice | 3 | 2016 | 12697 | 0.090 |
Why?
|
| Male | 7 | 2017 | 47109 | 0.090 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 2572 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 301 | 0.080 |
Why?
|
| Pregnancy, Multiple | 2 | 2002 | 37 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2012 | 524 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2207 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 889 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2005 | 764 | 0.070 |
Why?
|
| Sphingomyelins | 2 | 2001 | 15 | 0.070 |
Why?
|
| United States | 2 | 2019 | 8193 | 0.070 |
Why?
|
| Cocaine | 1 | 1989 | 84 | 0.070 |
Why?
|
| Phosphatidylcholines | 2 | 2001 | 49 | 0.070 |
Why?
|
| Endothelin-3 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Iodine Radioisotopes | 1 | 2008 | 145 | 0.070 |
Why?
|
| Fetal Blood | 2 | 2005 | 94 | 0.060 |
Why?
|
| Liver Diseases | 1 | 1989 | 249 | 0.060 |
Why?
|
| Phospholipases A2 | 1 | 2006 | 45 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2006 | 46 | 0.060 |
Why?
|
| Biomarkers | 1 | 2013 | 2022 | 0.060 |
Why?
|
| Length of Stay | 2 | 2020 | 878 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2006 | 272 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2008 | 349 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2006 | 303 | 0.050 |
Why?
|
| Nitrites | 1 | 2005 | 34 | 0.050 |
Why?
|
| Nitrates | 1 | 2005 | 35 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 1989 | 470 | 0.050 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2024 | 7 | 0.050 |
Why?
|
| Cobalt Radioisotopes | 1 | 2004 | 19 | 0.050 |
Why?
|
| Likelihood Functions | 2 | 2002 | 258 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 1998 | 1568 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2003 | 173 | 0.040 |
Why?
|
| Phosphatidylglycerols | 1 | 2001 | 4 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 2001 | 66 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 35 | 0.040 |
Why?
|
| Time Factors | 2 | 2000 | 5576 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 62 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2020 | 63 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2001 | 113 | 0.040 |
Why?
|
| Birth Weight | 1 | 2000 | 150 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 612 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 580 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 346 | 0.040 |
Why?
|
| Maternal Age | 1 | 1999 | 49 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 1123 | 0.040 |
Why?
|
| Federal Government | 1 | 1998 | 28 | 0.040 |
Why?
|
| Legislation, Medical | 1 | 1998 | 10 | 0.040 |
Why?
|
| Ethics | 1 | 1998 | 24 | 0.040 |
Why?
|
| Personhood | 1 | 1998 | 16 | 0.040 |
Why?
|
| Beneficence | 1 | 1998 | 36 | 0.040 |
Why?
|
| Oxygen | 1 | 2004 | 801 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 1998 | 72 | 0.030 |
Why?
|
| Prenatal Care | 2 | 1996 | 81 | 0.030 |
Why?
|
| Uterine Cervicitis | 1 | 2017 | 4 | 0.030 |
Why?
|
| Chorioamnionitis | 1 | 2017 | 23 | 0.030 |
Why?
|
| Prognosis | 2 | 1996 | 4116 | 0.030 |
Why?
|
| Personal Autonomy | 1 | 1998 | 125 | 0.030 |
Why?
|
| Placentation | 1 | 1997 | 11 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1997 | 26 | 0.030 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1996 | 20 | 0.030 |
Why?
|
| Sheep | 1 | 1996 | 204 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 1996 | 107 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 1948 | 0.030 |
Why?
|
| Oligohydramnios | 1 | 1995 | 2 | 0.030 |
Why?
|
| Placenta Diseases | 1 | 1995 | 18 | 0.030 |
Why?
|
| Acidosis | 1 | 1995 | 55 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1995 | 70 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 1995 | 120 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 1995 | 164 | 0.030 |
Why?
|
| Dexamethasone | 1 | 1996 | 318 | 0.030 |
Why?
|
| Societies, Medical | 1 | 1998 | 682 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1997 | 985 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1996 | 370 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 3213 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2002 | 4825 | 0.020 |
Why?
|
| Prednisone | 1 | 1993 | 251 | 0.020 |
Why?
|
| Aspirin | 1 | 1993 | 169 | 0.020 |
Why?
|
| Procainamide | 1 | 1991 | 4 | 0.020 |
Why?
|
| Enalapril | 1 | 1991 | 10 | 0.020 |
Why?
|
| Hydrops Fetalis | 1 | 1991 | 16 | 0.020 |
Why?
|
| Digoxin | 1 | 1991 | 21 | 0.020 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1991 | 21 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 679 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3598 | 0.020 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 1989 | 5 | 0.020 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1989 | 20 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 1989 | 43 | 0.020 |
Why?
|
| Parity | 1 | 1989 | 96 | 0.020 |
Why?
|
| Risk Assessment | 1 | 1996 | 2585 | 0.020 |
Why?
|
| Illinois | 1 | 1989 | 522 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1999 | 10962 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2003 | 42 | 0.010 |
Why?
|
| Litter Size | 1 | 2003 | 13 | 0.010 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2003 | 18 | 0.010 |
Why?
|
| Vaginosis, Bacterial | 1 | 2002 | 8 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 412 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2002 | 73 | 0.010 |
Why?
|
| Fibronectins | 1 | 2002 | 104 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 291 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2002 | 98 | 0.010 |
Why?
|
| Physical Examination | 1 | 2002 | 149 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 2001 | 74 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 720 | 0.010 |
Why?
|
| Risk Factors | 2 | 2002 | 6232 | 0.010 |
Why?
|
| Infant, Premature, Diseases | 1 | 1996 | 83 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 839 | 0.010 |
Why?
|
| Obstetric Labor, Premature | 1 | 1993 | 57 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 1996 | 377 | 0.010 |
Why?
|
| Logistic Models | 1 | 1996 | 1275 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1996 | 1783 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1991 | 63 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1991 | 212 | 0.010 |
Why?
|
| Incidence | 1 | 1996 | 1777 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1996 | 2013 | 0.000 |
Why?
|